Anaphore has entered into a partnership with Mitsubishi Tanabe Pharma Corporation to research, develop and commercialise novel protein therapies for autoimmune diseases.
The partnership will be built on Anaphore’s proprietary platform technology, which produces novel trivalent proteins called Atrimers, which have binding domains that can be used to bind to and activate or inhibit the target of interest.
Go deeper with GlobalData
Tanabe Research Laboratories, a subsidiary of Mitsubishi Tanabe Pharma, has the option to nominate two additional autoimmune targets for which Anaphore would develop potential protein therapeutics.
Under the agreement, Mitsubishi Tanabe Pharma will make a $5m upfront payment, and in addition, Anaphore will receive milestone payments totalling $110m and tiered royalties on sales.
The partnership will focus on biologic therapies for autoimmune disorders such as rheumatoid arthritis, inflammatory bowel disease and psoriasis.
Initial research activities will be undertaken by Tanabe Research Laboratories and Anaphore, while Mitsubishi Tanabe Pharma will be responsible for late-stage development and worldwide commercialisation.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
